WHITEHAWK THERAPEUTICS, INC. Increase (Decrease) in Accounts Payable and Other Operating Liabilities
WHITEHAWK THERAPEUTICS, INC. (WHWK) reported Increase (Decrease) in Accounts Payable and Other Operating Liabilities of -$817.12 thousand for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-11-10.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities · last filed 2020-11-10
- WHITEHAWK THERAPEUTICS, INC. increase (decrease) in accounts payable and other operating liabilities for the quarter ending 2020-09-30 was -$578.32K, a 50171.34% decline year-over-year.
- WHITEHAWK THERAPEUTICS, INC. increase (decrease) in accounts payable and other operating liabilities for the quarter ending 2020-06-30 was $437.06K.
- WHITEHAWK THERAPEUTICS, INC. increase (decrease) in accounts payable and other operating liabilities for the quarter ending 2020-03-31 was -$675.86K.
- WHITEHAWK THERAPEUTICS, INC. increase (decrease) in accounts payable and other operating liabilities for the quarter ending 2019-09-30 was $1.16K, a 99.83% decline year-over-year.
- WHITEHAWK THERAPEUTICS, INC. increase (decrease) in accounts payable and other operating liabilities for fiscal 2017 was $1.60M, a 415.80% increase from fiscal 2016.
- WHITEHAWK THERAPEUTICS, INC. increase (decrease) in accounts payable and other operating liabilities for fiscal 2016 was $311.10K.
| Period end | Increase (Decrease) in Accounts Payable and Other Operating Liabilities 3 month | Increase (Decrease) in Accounts Payable and Other Operating Liabilities 6 month | Increase (Decrease) in Accounts Payable and Other Operating Liabilities 9 month | Increase (Decrease) in Accounts Payable and Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2020-09-30 | -$578.32K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | -$141.26K derived: sum of 2 quarters · filed 2020-11-10 | -$817.12K 10-Q · filed 2020-11-10 | |
| 2020-06-30 | $437.06K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | -$238.80K 10-Q · filed 2020-08-12 | ||
| 2020-03-31 | -$675.86K 10-Q · filed 2020-05-07 | |||
| 2019-09-30 | $1.16K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | -$330.77K derived: sum of 2 quarters · filed 2020-11-10 | -$2.04M 10-Q · filed 2020-11-10 | |
| 2019-06-30 | -$331.93K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | -$2.05M 10-Q · filed 2020-08-12 | ||
| 2019-03-31 | -$1.71M 10-Q · filed 2020-05-07 | |||
| 2018-09-30 | $679.23K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $22.12K derived: sum of 2 quarters · filed 2019-11-07 | $52.52K 10-Q · filed 2019-11-07 | $1.06M derived: sum of 4 quarters · filed 2019-11-07 |
| 2018-06-30 | -$657.11K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | -$626.71K 10-Q · filed 2019-08-08 | $379.22K derived: sum of 3 quarters · filed 2019-08-08 | $1.11M derived: sum of 4 quarters · filed 2019-08-08 |
| 2018-03-31 | $30.40K 10-Q · filed 2019-05-09 | $1.04M derived: sum of 2 quarters · filed 2019-05-09 | $1.77M derived: sum of 3 quarters · filed 2019-05-09 | $652.52K derived: sum of 4 quarters · filed 2019-05-09 |
| 2017-12-31 | $1.01M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $1.74M derived: sum of 2 quarters · filed 2018-11-07 | $622.12K derived: sum of 3 quarters · filed 2018-11-07 | $1.60M 10-K · filed 2018-03-15 |
| 2017-09-30 | $729.42K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | -$383.81K derived: sum of 2 quarters · filed 2018-11-07 | $598.71K 10-Q · filed 2018-11-07 | $1.08M derived: sum of 4 quarters · filed 2018-11-07 |
| 2017-06-30 | -$1.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-14 | -$130.71K 10-Q · filed 2018-08-14 | $348.40K derived: sum of 3 quarters · filed 2018-08-14 | $251.65K derived: sum of 4 quarters · filed 2018-08-14 |
| 2017-03-31 | $982.52K 10-Q · filed 2018-05-15 | $1.46M derived: sum of 2 quarters · filed 2018-05-15 | $1.36M derived: sum of 3 quarters · filed 2018-05-15 | $1.39M derived: sum of 4 quarters · filed 2018-05-15 |
| 2016-12-31 | $479.11K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $382.36K derived: sum of 2 quarters · filed 2018-03-15 | $408.72K derived: sum of 3 quarters · filed 2018-03-15 | $311.10K 10-K · filed 2018-03-15 |
| 2016-09-30 | -$96.76K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-13 | -$70.39K derived: sum of 2 quarters · filed 2017-11-13 | -$168.02K 10-Q · filed 2017-11-13 | |
| 2016-06-30 | $26.36K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | -$71.26K 10-Q · filed 2017-08-10 | ||
| 2016-03-31 | -$97.63K 10-Q · filed 2017-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |